Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 17.33 SEK -4.31%
Market Cap: 809.2m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Moberg Pharma AB (publ)
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Moberg Pharma AB (publ)
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Moberg Pharma AB (publ)
STO:MOB
Interest Income Expense
kr2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Interest Income Expense
-kr115.2m
CAGR 3-Years
-23%
CAGR 5-Years
-133%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Interest Income Expense
kr73.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Interest Income Expense
-kr97.3m
CAGR 3-Years
-177%
CAGR 5-Years
-219%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Interest Income Expense
kr2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Interest Income Expense
-kr78.7m
CAGR 3-Years
-875%
CAGR 5-Years
-322%
CAGR 10-Years
N/A
No Stocks Found

Moberg Pharma AB (publ)
Glance View

Market Cap
794.2m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
0.6 SEK
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Moberg Pharma AB (publ)'s Interest Income Expense?
Interest Income Expense
2m SEK

Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Interest Income Expense amounts to 2m SEK.

What is Moberg Pharma AB (publ)'s Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
186%

Over the last year, the Interest Income Expense growth was 186%.

Back to Top